ACADIA Pharmaceuticals IncNASDAQ:ACAD
- LAST PRICE16.2050
- TODAY'S CHANGE (%)-0.3350 (-2.0254%)
- Bid / Lots16.1900/ 2
- Ask / Lots16.2200/ 2
- Open / Previous Close16.4200 / 16.5400
- Day Range
- 52 Week Range
- Volume104,421
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACAD |
|---|---|---|
| 09:32 ET | 9729 | 16.415 |
| 09:33 ET | 2275 | 16.35 |
| 09:35 ET | 7400 | 16.33 |
| 09:37 ET | 1960 | 16.355 |
| 09:39 ET | 3400 | 16.35 |
| 09:42 ET | 1300 | 16.275 |
| 09:44 ET | 4848 | 16.2796 |
| 09:46 ET | 600 | 16.23 |
| 09:48 ET | 5969 | 16.205 |
| 09:50 ET | 2241 | 16.2 |
| 09:51 ET | 2717 | 16.25 |
| 09:53 ET | 1753 | 16.23 |
| 09:55 ET | 1598 | 16.27 |
| 09:57 ET | 862 | 16.28 |
| 10:00 ET | 1936 | 16.253648 |
| 10:02 ET | 4690 | 16.2475 |
| 10:04 ET | 2154 | 16.24 |
| 10:06 ET | 2567 | 16.3 |
| 10:08 ET | 1664 | 16.27 |
| 10:09 ET | 1615 | 16.255 |
| 10:11 ET | 1378 | 16.23 |
| 10:13 ET | 1207 | 16.21 |
| 10:15 ET | 801 | 16.25 |
| 10:18 ET | 1163 | 16.22 |
| 10:20 ET | 684 | 16.21 |
| 10:22 ET | 250 | 16.205 |
Nov 21, 2024
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences, from 4:05PM ET on Thursday Nov 21, 2024 by Dow Jones
4:05PM ET on Thursday Nov 21, 2024 by Dow Jones
Nov 20, 2024
DJ Acadia Pharmaceuticals' Operating Chief Involuntarily Terminated Without Cause, from 5:20PM ET on Wednesday Nov 20, 2024 by Dow Jones
5:20PM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 15, 2024
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Friday Nov 15, 2024 by Dow Jones
4:05PM ET on Friday Nov 15, 2024 by Dow Jones
Nov 7, 2024
DJ ACADIA Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham, from 8:12AM ET on Thursday Nov 07, 2024 by Dow Jones
8:12AM ET on Thursday Nov 07, 2024 by Dow JonesDJ ACADIA Pharmaceuticals Price Target Maintained With a $27.00/Share by HC Wainwright & Co., from 7:48AM ET on Thursday Nov 07, 2024 by Dow Jones
7:48AM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ACADIA Pharmaceuticals Inc | 2.7B | 20.9x | --- |
Azenta Inc | 2.1B | -15.3x | --- |
Amicus Therapeutics Inc | 2.9B | -28.2x | --- |
Catalyst Pharmaceuticals Inc | 2.6B | 18.2x | --- |
Veracyte Inc | 3.1B | -284.7x | --- |
Twist Bioscience Corp | 2.5B | -13.0x | --- |
Company Information
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Contact Information
- Headquarters
- 12830 El Camino Real, Suite 400SAN DIEGO, CA, United States 92130
- Phone
- 858-558-2871
- Fax
- 858-558-2872
Executives
- Independent Chairman of the Board
- Stephen Biggar
- Chief Executive Officer, Director
- Catherine Owen Adams
- Chief Financial Officer, Executive Vice President
- Mark Schneyer
- Chief Operating Officer, Executive Vice President, Head of Commercial
- Brendan Teehan
- Executive Vice President, Company Secretary and Chief Legal Officer
- Jennifer Rhodes
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
|---|---|
Revenue (TTM) | $929.2M |
Shares Outstanding | 166.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.40 |
EPS | $0.78 |
Book Value | $2.62 |
P/E Ratio | 20.9x |
Price/Sales (TTM) | 2.9 |
Price/Cash Flow (TTM) | 19.3x |
Operating Margin | 12.08% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
